Skip to main content
Top
Published in: Current Bladder Dysfunction Reports 4/2020

01-12-2020 | Neurogenic Bladder | Neurogenic Bladder (C Powell, Section Editor)

The Evidence For and Against Prostate-Reducing Procedures for Men with Neurogenic Bladder

Authors: Timothy M. Han, Patrick J. Shenot, Alex Uhr, Lydia Glick, Akhil K. Das

Published in: Current Bladder Dysfunction Reports | Issue 4/2020

Login to get access

Abstract

Purpose of Review

The evaluation of anatomic bladder outlet obstruction due to benign prostatic hyperplasia in patients with neurogenic bladder dysfunction can be a challenging and complex process for urologists. Lower urinary tract symptoms are non-specific, and the attribution of symptoms to underlying neurologic disease may result in withholding potentially beneficial therapies and procedures from patients with benign prostatic hyperplasia. Conversely, the underlying neurologic disorder may have profound effects on lower urinary tract symptoms and quality of life and must be considered in patient management decisions. Thorough evaluation is necessary to evaluate male patients with concomitant benign prostatic hyperplasia and neurogenic bladder with careful attention to the underlying neurologic disease. While surgical management of anatomic bladder outlet obstruction has a clear role in carefully selected and thoroughly evaluated patients with neurogenic bladder, treatment strategies must be individualized for each patient. This review seeks to explore the role of prostate-reducing surgeries in management of patients with neurogenic bladder and to compile evidence for and against these procedures in this population.

Recent Findings

Only a few studies have been published exploring prostate-reducing surgery in the management of patients with neurogenic bladder, with no recent trials. These existing studies are poorly controlled and are characterized by small, heterogeneous study populations, retrospective design, and high risk of bias.

Summary

While some studies suggest positive outcomes from prostate-reducing surgery for management of patients with neurogenic bladder, more high-quality trials are needed.
Literature
1.
2.
go back to reference Pannek J, Berges RR, Cubick G, Meindl R, Senge T. Prostate size and PSA serum levels in male patients with spinal cord injury. Urology. 2003;62(5):845–8.CrossRef Pannek J, Berges RR, Cubick G, Meindl R, Senge T. Prostate size and PSA serum levels in male patients with spinal cord injury. Urology. 2003;62(5):845–8.CrossRef
3.
go back to reference Sakakibara R, Hamano S, Uchiyama T, Liu Z, Yamanishi T, Hattori T. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int. 2005;74(1):44–50.CrossRef Sakakibara R, Hamano S, Uchiyama T, Liu Z, Yamanishi T, Hattori T. Do BPH patients have neurogenic detrusor dysfunction? A uro-neurological assessment. Urol Int. 2005;74(1):44–50.CrossRef
4.
go back to reference Elsaesser E, Stoephasius E. Urological operations for improvement of bladder voiding in paraplegic patients. Paraplegia. 1972;10:68–77.PubMed Elsaesser E, Stoephasius E. Urological operations for improvement of bladder voiding in paraplegic patients. Paraplegia. 1972;10:68–77.PubMed
5.
go back to reference Koyanagi T, Arikado K, Tsuji I. Radical transurethral resection of the prostate for neurogenic dysfunction of the bladder in male paraplegics. J Urol. 1981;125(4):521–7.CrossRef Koyanagi T, Arikado K, Tsuji I. Radical transurethral resection of the prostate for neurogenic dysfunction of the bladder in male paraplegics. J Urol. 1981;125(4):521–7.CrossRef
6.
go back to reference Koyanagi T, Morita H, Takamatsu T, Taniguchi K, Shinno Y. Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol. 1987;137(1):72–6.CrossRef Koyanagi T, Morita H, Takamatsu T, Taniguchi K, Shinno Y. Radical transurethral resection of the prostate in male paraplegics revisited: further clinical experience and urodynamic considerations for its effectiveness. J Urol. 1987;137(1):72–6.CrossRef
7.
go back to reference Shinno Y. An electromyographic study of detrusor sphincter dyssynergia in neurogenic vesical dysfunction. Part 2. Changes after radical transurethral resection of prostate and response to alpha-adrenergic stimulation. Nihon Hinyokika Gakkai Zasshi. 1989;80(10):1443–50.PubMed Shinno Y. An electromyographic study of detrusor sphincter dyssynergia in neurogenic vesical dysfunction. Part 2. Changes after radical transurethral resection of prostate and response to alpha-adrenergic stimulation. Nihon Hinyokika Gakkai Zasshi. 1989;80(10):1443–50.PubMed
8.
go back to reference Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117–8.CrossRef Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117–8.CrossRef
9.
go back to reference Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRef Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.CrossRef
10.
go back to reference Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151:1336–41.CrossRef Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol. 1994;151:1336–41.CrossRef
11.
go back to reference • Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res. 2019;29(6):627–31 This study prospectively explored how often and how early bladder symptoms predate motor symptoms in multiple system atrophy.CrossRef • Sakakibara R, Panicker J, Simeoni S, et al. Bladder dysfunction as the initial presentation of multiple system atrophy: a prospective cohort study. Clin Auton Res. 2019;29(6):627–31 This study prospectively explored how often and how early bladder symptoms predate motor symptoms in multiple system atrophy.CrossRef
12.
go back to reference Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100–4.CrossRef Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100–4.CrossRef
13.
go back to reference Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease--should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.CrossRef Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease--should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.CrossRef
14.
go back to reference Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.CrossRef Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.CrossRef
15.
go back to reference Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, et al. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014;84(3):675–80.CrossRef Han HH, Ko WJ, Yoo TK, Oh TH, Kim DY, Kwon DD, et al. Factors associated with continuing medical therapy after transurethral resection of prostate. Urology. 2014;84(3):675–80.CrossRef
16.
go back to reference Moisey CU, Rees RWM. Results of transurethral resection of prostate in patients with cerebrovascular disease. Br J Urol. 1978;50:539–41.PubMed Moisey CU, Rees RWM. Results of transurethral resection of prostate in patients with cerebrovascular disease. Br J Urol. 1978;50:539–41.PubMed
17.
go back to reference Lum SK, Marshall VR. Results of prostatectomy in patients following a cerebrovascular accident. Br J Urol. 1982;54(2):186–9.CrossRef Lum SK, Marshall VR. Results of prostatectomy in patients following a cerebrovascular accident. Br J Urol. 1982;54(2):186–9.CrossRef
18.
go back to reference Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.CrossRef Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.CrossRef
19.
go back to reference Fjorback MV, Van Rey FS, Rijkhoff NJM, Nøhr M, Petersen T, Heesakkers JP. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2007;26(4):525–30.CrossRef Fjorback MV, Van Rey FS, Rijkhoff NJM, Nøhr M, Petersen T, Heesakkers JP. Electrical stimulation of sacral dermatomes in multiple sclerosis patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2007;26(4):525–30.CrossRef
20.
go back to reference Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S12–8.CrossRef Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S12–8.CrossRef
21.
go back to reference Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM. Functional treatments in multiple sclerosis. Curr Opin Neurol. 2011;24(3):250–4.CrossRef Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM. Functional treatments in multiple sclerosis. Curr Opin Neurol. 2011;24(3):250–4.CrossRef
22.
go back to reference Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202(3):592–8.CrossRef Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline Amendment 2019. J Urol. 2019;202(3):592–8.CrossRef
23.
go back to reference Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE. Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology. 2014;83(2):428–32.CrossRef Mitchell CR, Mynderse LA, Lightner DJ, Husmann DA, Krambeck AE. Efficacy of holmium laser enucleation of the prostate in patients with non-neurogenic impaired bladder contractility: results of a prospective trial. Urology. 2014;83(2):428–32.CrossRef
24.
go back to reference Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. Urology. 2016;97:208–11.CrossRef Lomas DJ, Krambeck AE. Long-term efficacy of holmium laser enucleation of the prostate in patients with detrusor underactivity or acontractility. Urology. 2016;97:208–11.CrossRef
25.
go back to reference Kavanagh A, Baverstock R, Campeau L, Carlson K, Cox A, Hickling D, et al. Canadian Urological Association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction–full text. Can Urol Assoc J. 2019;13(6):E157–76.PubMedPubMedCentral Kavanagh A, Baverstock R, Campeau L, Carlson K, Cox A, Hickling D, et al. Canadian Urological Association guideline: diagnosis, management, and surveillance of neurogenic lower urinary tract dysfunction–full text. Can Urol Assoc J. 2019;13(6):E157–76.PubMedPubMedCentral
26.
go back to reference •• Noordhoff TC, Groen J, Scheepe JR, BFM B. Surgical management of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction: a systematic review. Eur Urol Focus. 2019;5(5):875–86 This systematic review was unable to identify the optimal practice for surgical treatment of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction due to limited availability of high-quality studies.CrossRef •• Noordhoff TC, Groen J, Scheepe JR, BFM B. Surgical management of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction: a systematic review. Eur Urol Focus. 2019;5(5):875–86 This systematic review was unable to identify the optimal practice for surgical treatment of anatomic bladder outlet obstruction in males with neurogenic bladder dysfunction due to limited availability of high-quality studies.CrossRef
Metadata
Title
The Evidence For and Against Prostate-Reducing Procedures for Men with Neurogenic Bladder
Authors
Timothy M. Han
Patrick J. Shenot
Alex Uhr
Lydia Glick
Akhil K. Das
Publication date
01-12-2020
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2020
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-020-00615-y

Other articles of this Issue 4/2020

Current Bladder Dysfunction Reports 4/2020 Go to the issue

Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)

Antibiotic Prophylaxis in Pelvic Floor Surgery

Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)

The Role of Pelvic Neurophysiology Testing in the Assessment of Patients with Voiding Dysfunction

Global Health (K McCammon, Section Editor)

The Current Status of Global Urology